Fennec Pharmaceuticals Q3 EPS $(0.07) Beats $(0.11) Estimate, Sales $6.51M Beat $5.42M Estimate
Portfolio Pulse from Benzinga Newsdesk
Fennec Pharmaceuticals reported Q3 earnings per share (EPS) of $(0.07), beating the analyst consensus estimate of $(0.11) by 36.36%. This is a 77.42% increase over losses from the same period last year. The company also reported quarterly sales of $6.51 million, beating the analyst consensus estimate of $5.42 million by 20.20%.
November 06, 2023 | 11:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Fennec Pharmaceuticals reported better than expected Q3 earnings and sales, which could positively impact its stock price in the short term.
Fennec Pharmaceuticals reported Q3 earnings and sales that beat analyst estimates. This is generally seen as a positive signal by the market and could lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100